
|Videos|December 22, 2015
Dr. Eric Winer on Carboplatin and/or Bevacizumab in Triple-Negative Breast Cancer
Author(s)Eric Winer, MD
Eric P. Winer, MD, discusses the survival rates of women with early stage breast cancer who received bevacizumab and/or carboplatin.
Advertisement
Eric P. Winer, MD, chief of the Division of Women's Cancers, director of the Breast Oncology Program, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, discusses the survival rates of women with early stage breast cancer who received bevacizumab and/or carboplatin. Winer says that while studies are currnetly being done regarding bevacizumab's effecacy in breast cancer, those studies may not move forward due to this information.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
4
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
5








































